Teva Stock Drops 24% on Q2 Earnings Miss

Posted August 05, 2017

Teva Pharmaceutical Industries Limited presently has an average rating of "Hold" and an average target price of $42.23. Also, the current price highlights a discount of 30.85% to analysts' high consensus price target. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. The value of the company's investment in Teva Pharmaceutical Industries decreased from $12,726,000 to $9,728,000 decreasing 23.6% for the reporting period. The current share price indicates that stock is -57.43% away from its one year high and is moving -13.93% ahead of its 52-week low. One equities research analyst has rated the stock with a sell rating, twenty-one have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Analysts set a 12-month price target of $23.81 a share.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company's stock had a trading volume of 78,646,923 shares.

Teva Pharmaceutical Industries Limited (TEVA) waking on thin line between bulls and bears tracks and with several factors it's pulling towards optimistic side to some extend but some take to pessimistic side. The stock has a 50 day moving average of $31.96 and a 200-day moving average of $32.34. The company rocked its 52-Week High of $55.79 and touched its 52-Week Low of $23.33. Lincluden Management Ltd. increased its position in Teva Pharmaceutical Industries by 7.8% in the fourth quarter.

In premarket trading on the stock market today, Teva fell almost 9% to 28.55.

Israeli drugs group, Teva Pharmaceutical Industries revealed that a steeper than expected drop in second-quarter earnings on Thursday, due to weaker prices in the United States, and cut its interim dividend by 75 percent. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. During the same quarter a year ago, the business posted $1.25 EPS. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Outperform" rating given on Wednesday, April 5 by Cowen & Co.

TRADEMARK VIOLATION WARNING: "Teva Pharmaceutical Industries Limited (TEVA) PT Set at $27.00 by Cantor Fitzgerald" was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of global trademark & copyright laws. The legal version of this article can be accessed at Institutional investors and hedge funds own 56.20% of the company's stock.

In early Aug 2016, Teva acquired Allergan's generics business - Actavis Generics and in Oct 2016 it acquired the latter's Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S. Bank Hapoalim BM now owns 11,673 shares of the company's stock valued at $375,000 after buying an additional 980 shares during the period.

For the past 5 years, Teva Pharmaceutical Industries Limited's EPS growth has been almost -53%. Guggenheim Capital LLC now owns 40,276 shares of the company's stock worth $1,460,000 after buying an additional 446 shares during the last quarter. Finally, Zacks Investment Research raised Teva Pharmaceutical Industries from a "sell" rating to a "hold" rating in a research report on Monday, July 17th. Overall, 106.48 Million shares exchanged hands versus its average trading volume of 7.85 Million shares.

Teva has been in hot water since February, when former CEO Erez Vigodman stepped down suddenly at what was already an unsteady time for the company. The Company operates through two segments: Generic medicines and Specialty medicines.